Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Net Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Net Margin for 7 consecutive years, with 214.09% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 51460.0% to 214.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 57.24%, a 53588.0% increase, with the full-year FY2025 number at 57.24%, up 53588.0% from a year prior.
  • Net Margin was 214.09% for Q4 2025 at Beam Therapeutics, up from 1162.38% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 214.09% in Q4 2025 to a low of 3359333.33% in Q1 2021.
  • A 5-year average of 232209.62% and a median of 685.51% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: crashed -283041667bps in 2021, then surged 335851248bps in 2022.
  • Beam Therapeutics' Net Margin stood at 126.71% in 2021, then tumbled by -51bps to 191.39% in 2022, then skyrocketed by 124bps to 45.16% in 2023, then tumbled by -765bps to 300.51% in 2024, then surged by 171bps to 214.09% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Net Margin are 214.09% (Q4 2025), 1162.38% (Q3 2025), and 1208.26% (Q2 2025).